Delivery Order HHSO100201300005I-HHSO10033003T
Award Date
9/30/16
Potential Completion Date
9/30/21
Potential Value
$38M
Awardee
Partner Therapeutics, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bridgewater, NJ 08807, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract award to Partner Therapeutics, Inc. is for a Task Order under the HHS Colony Stimulating Factor 2013-2018 Indefinite Delivery/Indefinite Quantity (ID/IQ) contract. The task order, valued at $13,943,972.12, is for the acquisition of a Colony Stimulating Factor (G- or GM-CSF) as a medical countermeasure for neutropenia. The contract is a Firm Fixed Price Delivery Order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the Department of...
This is a federal contract award to Amgen USA Inc., a division of the biotechnology company Amgen, by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. The contract, valued at $37,675,456.54, is for the acquisition of a colony stimulating factor, either G-CSF or GM-CSF, to mitigate neutropenia arising from exposure to ionizing radiation. This is a delivery order contract under the HHS Colony Stimulating Factor 2013-2018 IDIQ contract, a...
This is a $83,515,143.92 firm fixed-price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Partner Therapeutics, Inc., a for-profit biopharmaceutical company in Lexington, Massachusetts. The contract is for the supply of LEUKINE 250MCG VIL INJ (5PKG), a critical medical countermeasure. This delivery order is part of Partner Therapeutics' broader contract...
This is a $999,406,548.42 firm fixed price definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Amgen USA Inc., a leading biotechnology company. The contract is for the treatment of thrombocytopenia or platelet loss in a mass casualty event, with the procured therapeutic to be delivered to the Strategic National Stockpile as vendor managed inventory. The contract exercises option periods 3 for...
This is a $59,026,989.30 delivery order awarded to Partner Therapeutics, Inc., a for-profit biopharmaceutical company, by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The order is to provide LEUKINE 250MCG/VIL INJ, an injectable drug, with a completion date of March 29, 2024. Partner Therapeutics has previously held federal contracts to provide pharmaceuticals and biologics, including a $22.2 million order for LEUKINE to treat...
This is a $13,675,055.00 firm fixed price contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Partner Therapeutics, Inc., a biopharmaceutical company based in Lexington, Massachusetts. The contract is for the advanced development of Leukine, monocyte human leukocyte antigen-DR (mHLA-DR), and other biomarkers predictive of sepsis. The objective is to confirm Leukine's safety in sepsis patients, inform...
This federal contract award, valued at $23,257,222.47, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The purpose of the contract is to provide medical countermeasures (MCMs), such as vaccines and adjuvants, for pandemic preparedness and response. The contract was awarded to Seqirus Inc., a division of the global biotechnology company CSL Seqirus, which is a leading provider of MCMs to the...
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Peprotech Inc., a biotechnology company that develops and manufactures cytokine products. The $3,560.00 Firm Fixed Price Purchase Order is for the delivery of recombinant human M-CSF 250 ug, a biological reagent material used in research. Peprotech Inc. has received several prior awards from the Department of Health and Human Services (HHS), National Institutes of Health (NIH), and other...
This federal contract award establishes services for H5 pandemic readiness through the acquisition of medical countermeasures (MCMs) for pandemic influenza and emerging diseases preparedness and response. The contract, valued at $94,587,688.20, was awarded to the prime contractor Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract is a delivery order issued under a larger Indefinite Delivery Contract (IDC) with the Department of Health and Human Services'...
This is a delivery order awarded to The Mitre Corporation, a not-for-profit organization, by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) under the Health FFRDC services contract (75FCMC18D0047). The contract has a total potential value of $9,650,506.00 and a period of performance through August 30, 2025. The purpose of this award is to support a path forward for building an industrial and manufacturing base for medical...